Myocardial metabolism: Pharmacological manipulation in myocardial ischaemia

Journal of Association of Physicians of India

Volumn 53, Issue JUN, 2005, Pages 552-560

  Mitra, B ^a   Panja, M ^a  

^a INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT;

DRUG EFFECT; HEART; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HUMAN; METABOLISM; REVIEW;

CARDIOVASCULAR AGENTS; HEART; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIUM;

EID: 24644471493     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Lipincott Williams and Wilkins. Coron Artery Dis 2001;12(suppl); S3-S7.
2. Liedlke AJ. Alteration in carbohydrates and lipid metabolism in acute ischemic heart. Prog Cardiovascular Dis 1981; 23:321-26.
3. Stanley WC, Lopaschuk GD, Hall JL, Mc Cormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischemic condition. Potential for pharmacological interventions. Cardiovascular research 1997;33:243-57.
4. Van Wylen DG, Willis J, Sodhi J, et al. Cardiac micro dialysis to estimate interstitial adenosine and coronary blood flow. Am J Phy 1990;258;H 1642-49.
5. Crea F. Gaspardonot, and New look to old symptoms; Angina pectoris: Circulatiion 1997;96:3766-73.
6. Fabito A. Fabiato F.Effect of pH on the myofilaments and the sarcoplasmic reticulum of skinned cell from cardiac and skeletal muscles. J Physiol 1978;276:233-55.
7. Murphy E, PerlmanM, London RE, et al. Amiloride delays the ischemia induced rise in cytosolic free calcium. Circulation (Res) 1991; 68:1250-58.
8. Hernandez LA, Stanly WC, et al. Pyruvate dehydrogenase activity and malonyl CoA levels in normal and ischemic swine myocardium; effect of dichloroacetate. J Mol Cell Cardiol 1996;29:905-14.
9. Opie LH, Tansey M, Kennlly BM. Proposed Metabolic vicious circle in patients with large myocardial infarcts andhigh plasma free- fatty acid concentration. Lancet 1977;2:890-2.
10. King X, Opie X. Glucose and glycogen utilization in myocardial ischemia-changes in metabolism and consequences for the myocyte. Mol cell Biochem 1998;180:3-26.
11. Taegtmeyer H. Is there a rationale for glucose-insulin-Potassium; therapy in acute myocardial infarction? Cardiol Rev 1995;26:307-13.
12. Opie LH. The glucose hypothesis; relation to acute myocardial ischemia. J Mol Cell Cardiol 1970;1:107-15.
13. Vano versehelde, J-LJ, Janier MF, Bakke JE, et al. Rate of glycolysis deriving ischemic determines extent of ischemic injury and functional recovery after reperfusion. Am J Physiol 1994,267: H 1785-94.
14. Eberli FR, Winberg EO, et al. Protective effect of increased glycolytic substrate against systolic and diastolic dysfunction and increased coronary resistance from prolonged global underperfusion in isolated rabit heart perfused with erythrocyte suspension. Cir Res 1991;68:466-81.
15. Glucose-Insulin -Potassium therapy for treatment of acute myocardial infarction, Farzin Fath-ordoubadi. Circul 1997;96:1152-56.
16. Diaz R,Paocasso EA, Piegasis, et al. Metabolic modulation of acute myocardial infarction, the ECLA(Estudios Cardiologicos Latino Ameriac) collaborative group. Circula 1998;98;2227-34.
17. Malmberg K, Ryden L, et al. Randomized trials of insulin glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction,effect on mortality at one year. J Am College Cardiol 1995;26;57-65.
18. Runnman EM, Weis JN. Exogenous glucose utilization is superior to glycogenolysis at preserving cardiac function during hypoxia. 1988;(78)(SuppII): II-261 Abstract.
19. Doorey AJ, Barry WH, et al. The effect of inhibition of oxidative phosphorylation and glycolysis on contractility and high energy phosphate content in cultured chick heart cells. Circ Res 1983;53;192-201.
20. Hasion Y, Barry WH. Myocardial metabolism inhibition and membrane potential, contraction and potassium uptake. Am J Physio 1984;247:H 322-29.
21. Handeresion AH, Most AS, et al. Depression of myocardial contractility in rat by free fatty acid during hypoxia. Circu Res 1970;26:439.
22. Saman S, CoetzeeWA, et al. Inhibition by stimulated ischemia or hypoxia of delayed after depolarization provoketed by cAMP; significance for ischemic and reperfusion arrythmias. J Mol Cell Cardiol 1988;20:91-95.
23. Kurien VA, Oliver MF. A metabolic cause of arrhythmias during acute myocardial hypoxia. Lancet 1970;1:813-15.
24. Apstein CS, Deckelbauml, Muchler M, et al. Graded global ischemia and reperfusion cardiac function and lactate metabolism. Circulation 1977;55:864-72.
25. Daui G Catalan I, Averna M.Thromboxane biosynthesis and platelet function in type II diabetis mellitus. NEJM 1990;322;1769-74.
26. Gradinae S, Coleman GM, et al. Improved cardiac function with glucose-insulin -potassium after aortocoronary bypass grafting. Am Thorasic Surgery 1989;48:484-9.
27. Ramasamy R. Metabolic effect of aldose reductase inhibition during low flow ischemia and reperfusion. Am J Physiol 275:195-203.
28. Trueblood NA, Ramaswamy R. Aldose reductase inhibition improves the altered glucose metabolism of isolated diabetic rat heart. Am J Physiol 1998;275;75-83.
29. Ramashwamy R, Oates PJ. Aldose reductase inhibition protects diabetic and non diabetic rat heart from ischemic injury. Diabetis 1997;46;292-300.
30. Linn BO, Page Ac. Wong EL. Isolation and distribution of coenzyme Q 10 in animal tissue. J Am Chem Soc 1959;81:4007-10.
31. Takeshige K,Takayanagi K, et al. Reduced coenzyme Q10 as an antioxidant of lipid peroxidation in bovine heart mitocondria in Yamamura Y,Folkers K,Ito Y; Biochemical and clinical aspects of CO enzyme Q10.Vol2.Elsovier/North Holland Biomedical Press. Amsterdam 1980;15-26.
32. Kbayashi M,Shimoura Y, et al. Structural effects of ubiquinones on the mitochondrial inner membrane. J Appl Biochem 1980;2:270-79.
33. Katigiri T, Sasai Y, Kobiyash T, et al. Protective effect of co enzyme Q10 in the acute ischemic myocardial injury, Biomedical and clinical aspects of co Q10.Vol3,Elsevier/ North Holland Biomedical Press. Amsterdam 1981;349-59.
34. Ernster L, Nelson BD. Functions of CO enzyme Q in Folkers K ,Yamamura Y (eds); Biomedical and clinical aspects of co Q10 Vol 3 Elsevier/ North Holland Biomedical Press. Amsterdam 1981;159-68.
35. Scharde F,Welzel D, et al. Effect of co- Q10 on ischemia induced ST segment depression :a blind placebo -controled cross over study; ,Biomedical and clinical aspects of co Q10.Vol5,Elsevier/North Holland Biomedical Press. Amsterdam 1985;385-94.
36. Kobayashi M, Shimomura Y, et al.Structural effect of ubiquinones on the mitochondrial inner membrane. J Appl Biochem 1980;2:270.
37. Sugiama S, Kitazawa M, et al. Anti oxidative effect of Co enzyme Q10. Experientia 1980;36-1002.
38. Mc clellan KJ, Plosker GL.Trimetazidine; a review of it's use in stable angina pectoris and other coronary condition. Drugs 1999;58:143-57.
39. Porin M, Harpey C, et al. Lack of effect of trimetazidine on systemic hemodynamics in patients with coronary artery disease-a placebo controlled study clin trials. Mentaanal 1994;29(1):49-56.
40. Almazov N, Shlyakhto E. The anti ischemic effect of myocardial cytoprotector trimetazidine, clinical and biochemical comparison. J Am Coll Cardiol 1998;35:3243.
41. Management of stable angina pectoris. Recomendation of the task force of the Europian Society of Cardiology. Eur Heart J 1989;1997;18:394-13.
42. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACPASIM guide line for the management of patients with chronic stable angina. J Am Coll Cardiol 1999;33:2092-297.
43. Schonekers BO, Allard MF, et al. Propionyl l carnitine improvement of hypertrophied heart function is accompanied by an increase in carbohydrate oxidation. Circulation Res 1995;77:726-34.
44. Stanley WC, Lopaschuk GD, Hall JL. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions; potential for pharmacological interventions. Cardiovas Res 1997;33:243-57.
45. Sellier P, Duong TC, Ourbak P. The effects of trimetazidine on ergometric parameter in exercise induced angina. Controlled multicentric double blind verses placebo study. Arch Mal Coeur Vaiss 1986;79:1331-36.
46. Sellier P, Audovier P, Payer B, Doung TC. Ergometric effect of single administration of trimetazidine. Presse Med 1986;15:1771-74.
47. Fantini E, Demaison L, Sentex E. Some biochemical aspect of the protective effect of trimetazidine on rat cardio myocyte during hypoxia and reoxygenation. J Mol Cell Cardiol 1994;26:949-58.
48. Marchetti G, Merlo L. Myocardial uptake of free fatty acid and carbohydrates after beta adrenergic blockade. Am J Cardiol 1968;22:310-14.
49. Glavino VV, Masters TN. The effect of intracoronary nor epinephrine on cardiac metabolism before and after beta adrenergic blockade. Feder Proe 1967;26:771-79.
50. Westera G, Vander wall EE, et al. Metabolic consequences of beta adrenergic receptor blockade for the acutely ischemic dog myocardium. Nuklearemedicine 1984;23:35-40.
51. Frishman WH.Secondery prevention of myocardial infarction; role of beta adrenergic blockers and angiotensin converting enzymes inhibitors (Review). Am Heart J 1999;137-3-25-934.
52. Rett K Wicklmayr M, et al. Insulin induced glucose transporter (GLUT1,GLUT4) translocation in cardiac muscle tissue is mimicked by bradykinin. Diabetes 1996;45(suppl):S66-69.
53. Theroux P. Protection of myocardial cell during ischemia. Am J Cardiol 1999;83:3G-9G.
54. Avkiran M. Rational basis for use of Sodium Hydrogen Exchanger inhibitors in myocardial ischemia. Am J Cardiol 1999;83:10G-17G.
55. Theroux P, Chaitman BR. Inhibition of the sodium Hydrogen Exchanger with Cariporide to prevent myocardial infarction in high risk ischemic situation.(GUARDIAN trials) Circulation 2000;102:3032-38.
56. Frolich J, Karmazyn M. The sodium-hydrogen exchanger revisited; an update on sodium-hydrogen exchange regulation and the role of the exchanger in hypertension and cardiac function in health and disease. Cardiovascular Res 1997;36;138-48.